Petrus Trust Company LTA Acquires New Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Petrus Trust Company LTA has acquired a new stake in Intuitive Surgical, Inc., purchasing 1,283 shares valued at approximately $635,000.
• Institutional investors now own 83.64% of Intuitive Surgical's stock, indicating strong confidence in the company's future prospects.
• Analysts have recently raised their price targets for Intuitive Surgical, with a consensus average target price of $595.95, reflecting positive sentiment towards the stock's performance.

Petrus Trust Company LTA acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,283 shares of the medical equipment provider's stock, valued at approximately $635,000.

A number of other large investors have also recently made changes to their positions in the business. Chilton Capital Management LLC lifted its position in shares of Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 43 shares in the last quarter. Global Financial Private Client LLC lifted its position in shares of Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 38 shares in the last quarter. Elite Financial Inc. bought a new position in shares of Intuitive Surgical during the first quarter valued at about $26,000. LFA Lugano Financial Advisors SA bought a new position in shares of Intuitive Surgical during the first quarter valued at about $30,000. Finally, TD Capital Management LLC lifted its position in shares of Intuitive Surgical by 300.0% during the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 45 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ISRG shares. Royal Bank Of Canada reissued an "outperform" rating and set a $615.00 price target on shares of Intuitive Surgical in a research report on Tuesday, August 19th. Evercore ISI raised their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Wells Fargo & Company raised their price target on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research report on Wednesday, July 23rd. Finally, Truist Financial raised their price target on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Stock Performance

ISRG stock traded down $5.98 during mid-day trading on Friday, hitting $449.87. The company had a trading volume of 771,439 shares, compared to its average volume of 2,016,717. The firm has a market cap of $161.27 billion, a PE ratio of 62.74, a price-to-earnings-growth ratio of 4.72 and a beta of 1.61. The stock's fifty day moving average price is $487.55 and its two-hundred day moving average price is $509.57. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company's revenue was up 21.4% on a year-over-year basis. During the same quarter last year, the company earned $1.78 earnings per share. Equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares in the company, valued at $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy L. Ladd sold 336 shares of Intuitive Surgical stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total transaction of $157,956.96. Following the completion of the transaction, the director owned 1,074 shares of the company's stock, valued at $504,898.14. The trade was a 23.83% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,224 shares of company stock worth $21,716,492 over the last quarter. Corporate insiders own 0.70% of the company's stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.